{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"109"},{"groupId":"OG001","value":"76"}],"title":"Negative post-baseline"},{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"3"}],"title":"Transiently positive post-baseline"},{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"}],"title":"Persistently positive post-baseline"}],"denoms":[{"counts":[{"groupId":"OG000","value":"112"},{"groupId":"OG001","value":"80"}],"units":"Participants"}],"title":"Baseline Negative"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"}],"title":"Negative post-baseline"},{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}],"title":"Transiently positive post-baseline"},{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}],"title":"Persistently positive post-baseline"}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"}],"units":"Participants"}],"title":"Baseline Positive"}],"denoms":[{"counts":[{"groupId":"OG000","value":"114"},{"groupId":"OG001","value":"81"}],"units":"Participants"}],"description":"Participants who were tested positive for ATA at any time post-baseline were considered to be transiently positive or persistently positive if \\>=2 consecutive samples were confirmed as positive.","groups":[{"description":"Participants in Cohort 1 had received prior treatment with platinum-containing chemotherapy. Enfortumab vedotin, at a dose of 1.25 mg/kg, was administered to participants as an IV infusion over approximately 30 minutes on Days 1, 8, and 15 of each 28-day cycle.","id":"OG000","title":"Enfortumab Vedotin - Cohort 1"},{"description":"Participants in Cohort 2 had received no platinum-containing chemotherapy were ineligible for treatment with cisplatin at the time of enrollment. Enfortumab vedotin, at a dose of 1.25 mg/kg, was administered to participants as an IV infusion over approximately 30 minutes on Days 1, 8, and 15 of each 28-day cycle.","id":"OG001","title":"Enfortumab Vedotin - Cohort 2"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Safety Analysis Set: Participants who received at least one dose of enfortumab vedotin. Here, 'Overall Number of Participants Analyzed' signifies ATA subset (participants with a baseline and at least one post-baseline sample). Here, 'Number Analyzed' signifies participants evaluable for specified rows.","reportingStatus":"POSTED","timeFrame":"The median duration of treatment was 4.60 months for Cohort 1 [full range: 0.5, 29.4 months] and 5.98 months for Cohort 2 [full range: 0.3, 24.6 months]","title":"Incidence of Antitherapeutic Antibody (ATA)","type":"SECONDARY","unitOfMeasure":"Participants"}